Go to content
UR Home

Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP)

Faehling, Martin ; Schumann, Christian ; Christopoulos, Petros ; Hoffknecht, Petra ; Alt, Jürgen ; Horn, Marlitt ; Eisenmann, Stephan ; Schlenska-Lange, Anke ; Schütt, Philipp ; Steger, Felix ; Brückl, Wolfgang M. ; Christoph, Daniel C.


Background: Following the PACIFIC trial, durvalumab has been approved by the European Medicines Agency (EMA) for consolidation of locally advanced PD-L1-positive NSCLC after chemoradiotherapy (CRT). Patients were treated with durvalumab in the EAP from 22.11.2017 to 15.10.2018 allowing analysis of its efficacy and safety. Methods: Data from 56 centres were analysed for adverse events (AE), ...


Owner only: item control page
  1. Homepage UR

University Library

Publication Server


Publishing: oa@ur.de
0941 943 -4239 or -69394

Dissertations: dissertationen@ur.de
0941 943 -3904

Research data: daten@ur.de
0941 943 -5707

Contact persons